The partnership to further international distribution of healthcare and vital pharmaceutical products
Abu Dhabi, UAE – July 12, 2022:AD Ports Group and Hayat Biotech signed a Memorandum of Understanding (MoU) to support Hayat Biotech’s global logistics and distribution efforts through AD Ports Group’s advanced pharma logistics network, which includes its cold & ultra-cold pharma hub based in KIZAD. Specifically, the partnership will help facilitate Hayat Biotech’s efforts to set up manufacturing centres around the globe and provide logistics solutions to serve its international markets.
The initial element of the agreement encapsulates shipping of strategic construction supplies, including containers, machinery, raw materials, and equipment, to support the construction of Hayat Biotech’s global biopharmaceutical manufacturing facilities. Once fully completed, the facilities will produce a number of vital biopharmaceutical products, including the Hayat-Vax vaccine, the first indigenously produced COVID-19 vaccine in the UAE and the Arab world.
As part of the collaboration, the distribution will be handled by the HOPE Consortium, an Abu Dhabi-led partnership which operates one of the largest and most complete end-to-end pharma supply chains on the market today.
Captain Mohamed Juma Al Shamisi, Managing Director and Group CEO of AD Ports Group, and Chairman of the HOPE Consortium’s Executive Committee, said: "As a nation, the UAE continues to take significant steps towards enabling global access to pharmaceutical products and supplies. Thanks to our partnership with Hayat Biotech, we are cementing the pivotal role that AD Ports Group and the HOPE Consortium are playing in supporting our healthcare industry’s efforts to serve communities and markets all around the world.”
He added: “AD Ports Group continues to deliver on our leadership’s vision of establishing Abu Dhabi as a global life sciences hub, and our partnership with Hayat Biotech is another important milestone along our journey towards achieving that goal.”
Robert Sutton, CEO of Logistics Cluster, AD Ports Group, said: “We are pleased to leverage our complete end-to-end logistics solutions, which cover everything from transportation and storage, to monitoring and delivery of pharma supplies, anywhere around the world. Capitalising on Abu Dhabi’s strategic position as a global gateway, we are working together to help position the Emirate as a leading global logistics hub for the life sciences sector.”
Naser Al Yammahi, Deputy CEO, Hayat Biotech,said: “The world is facing fundamental challenges that are affecting our wellbeing, health, and quality of life; therefore, we made it our responsibility to deliver innovative biotechnological capabilities around the globe. Thanks to the partnership with AD Ports Group, we are looking to further expand our distribution network to deliver necessary biopharmaceutical products to improve the health of our nation and across the globe.”
As a UAE-based company, Hayat Biotech, a Joint Venture between Abu Dhabi’s G42 and Sinopharm CNBG, focuses on the development of life sciences through advanced clinical trials, medical R&D, distribution of new pharmaceutical products, and vaccines. The company began locally-producing the Hayat-Vax vaccine in March 2021, which has been distributed worldwide, in part, by the HOPE Consortium partnership. Last year, Hayat Biotech announced the development of a purpose-built research and development hub for life sciences, biotechnology and vaccine production. Set up in KIZAD, the facility will be capable of producing over 200 million vaccine doses annually.
AD Ports Group operates one of the largest and most advanced supply chains in the region supporting multiple industry sectors, including construction and pharma. As part of its Logistics Cluster’s value offering, it provides fully-integrated pharma logistics solutions by leveraging the Group’s broad portfolio of assets & services, supported by advanced digital technology, a modern fleet of 400+ vehicles, and a network of world-class global logistics partners.
Alongside the Department of Health – Abu Dhabi, Etihad Cargo, Maqta Gateway, Rafed, and SkyCell, AD Ports Group is one of the founding members of the HOPE Consortium, which is helping lead the distribution of COVID-19 vaccines to all parts of the globe. Thanks to the strength, commitment, and the collective capabilities of its members, the partnership has handled over 250 million vaccine doses across 60 countries.
During his last visit to Abu Dhabi, the Microsoft founder, philanthropist, and humanitarian Bill Gates commended the advanced vaccine warehousing facility in KIZAD, operated by AD Ports Group’s Logistics Cluster. He highlighted the importance of this initiative in successfully resolving some of the major challenges associated with vaccine distribution and in delivering millions of vaccines to communities in need.
Thank you for your interest in our Investor downloads. You will be added to our investor database to receive updates from our investor relations teams by filling in the form.
This website contains general information about Abu Dhabi Ports PJSC (AD Ports Group) (the “Company”). The contents have been made available to you solely for information purposes and does not purport to be complete. By reading information on this website you agree to be bound as follows: nothing on this website shall constitute or deemed to constitute an invitation to invest or otherwise deal in securities in the Company.
Any investor or prospective investor considering making a transaction of securities in the Company should consult with its own counsel and advisers as to all financial, legal, tax, and related matters concerning an investment in such securities.
This website contains forward‐looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements including, without limitation, those regarding the financial position, business strategy, plans, targets and objectives of the management of the Company for future operations, including development plans and objectives. Such forward‐looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company’s ability to implement and achieve results set out in such forward‐looking statements and which may cause actual results and developments to be materially different from any forecast, opinion or expectation expressed on this website.
By clicking Accept, I understand that I may be contacted by AD Ports Group and Affiliates in relation to this event and other similar events and services relevant to my industry. By registering for this event, I acknowledge that AD Ports Group and Affiliates may contact me as described herein and as otherwise set out in the Privacy Policy and in accordance with stated Terms and Conditions